Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GeRx-941
- Development stage
- Preclinical
- Lead developer
- Gelteq
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GeRx-941 is an oral gel formulation of the antiparasitic drug praziquantel, developed by Gelteq using its proprietary ingestible gel platform. The formulation is designed for veterinary use, specifically targeting tapeworm infections in dogs. By utilizing Gelteq's gel-based delivery technology, GeRx-941 aims to improve palatability, ease of administration, and bioavailability compared to traditional tablet formulations. The drug is currently in clinical development, with Gelteq pursuing an Abbreviated New Animal Drug Application (ANADA) regulatory pathway with the FDA.
- Other names
- praziquantel edible gelpraziquantel oral gel
02
Targets
TRP (TRP channels)CaV (Voltage-gated calcium channel protein complex)
Beyond the preview
Go deeper on GeRx-941.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeRx-941.